Madrigal Pharmaceuticals Inc MDGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDGL is a good fit for your portfolio.
News
-
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
-
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
-
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
-
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
-
Madrigal's stock surges as FDA approves first drug for liver disease MASH
-
Madrigal Shares Leap Premarket on First FDA NASH Green Light
-
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA
Trading Information
- Previous Close Price
- $283.46
- Day Range
- $276.63–289.91
- 52-Week Range
- $119.76–299.98
- Bid/Ask
- $284.09 / $284.49
- Market Cap
- $6.06 Bil
- Volume/Avg
- 167,769 / 435,257
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 376
- Website
- http://www.madrigalpharma.com
Comparables
Valuation
|
Metric
|
MDGL
|
MORF
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.91 | 4.58 | 3.31 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MDGL
|
MORF
|
EWTX
|
|---|---|---|---|
Quick Ratio | 9.26 | 23.71 | 36.49 |
Current Ratio | 9.39 | 24.13 | 37.08 |
Interest Coverage | −31.95 | — | — |
Quick Ratio
MDGL
MORF
EWTX
Profitability
|
Metric
|
MDGL
|
MORF
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −74.33% | −20.07% | −23.18% |
Return on Equity (Normalized) | −125.94% | −20.72% | −24.45% |
Return on Invested Capital (Normalized) | −95.71% | −24.50% | −28.92% |
Return on Assets
MDGL
MORF
EWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Nlftzsfpw | Cvzm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pzlxrnnb | Jfhyl | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zzktwgw | Yplzf | $118.7 Bil | |||
| Moderna Inc
MRNA
| Nqywbmf | Lqxc | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hwbzwcmn | Gtrzdb | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Jdnympj | Qyhg | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Wzprjsmt | Mzhsf | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mhnyqvq | Ympqml | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tcfycpqfj | Wvyh | $15.0 Bil | |||
| Incyte Corp
INCY
| Bjzxslrv | Znqzjwy | $13.5 Bil |